Institution Directory

Clinical trials at Roswell Park Comprehensive Cancer Center

Sites in Buffalo, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

527

Shown on this page

Current sort

Live official records

Conditions: Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue, Clear Cell Sarcoma of Soft Tissue, Ewing Sarcoma, Hepatoblastoma, Hepatocellular Carcinoma, Osteosarcoma, Recurrent Adrenal Cortical Carcinoma, Recurrent Alveolar Soft Part Sarcoma, Recurrent Clear Cell Sarcoma of Soft Tissue, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Kidney Wilms Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Renal Cell Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Medullary Carcinoma, Refractory Adrenal Cortical Carcinoma, Refractory Alveolar Soft Part Sarcoma, Refractory Clear Cell Sarcoma of Soft Tissue, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Renal Cell Carcinoma, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Medullary Carcinoma, Refractory Wilms Tumor, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Neoplasm, Thyroid Gland Medullary Carcinoma, Wilms Tumor
Interventions: Cabozantinib, Cabozantinib S-malate, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 30 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 142
States / cities: Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 104 more

Conditions: Early Stage Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Lymph Node Biopsy, Positron Emission Tomography, Stereotactic Body Radiation Therapy, Survey Administration; Procedure · Radiation · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cigarette Smoking-Related Carcinoma, E-Cig Use
Interventions: Effectiveness of different recruitment approaches, Choice of study completion locations, Cannabis Engagement Assessment, E-cigarette dependence Scale, Nicotine dependence Scale, Co use practices QUestionnaire; Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 25 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Lung Carcinoma
Interventions: Biospecimen Collection, Montanide ISA 51 VG, Questionnaire Administration, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 1 more

Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult L1 Acute Lymphoblastic Leukemia, Adult L2 Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Methotrexate, Methylprednisolone, Peripheral Blood Stem Cell Transplantation, Prednisone, Sirolimus, Tacrolimus, Total-Body Irradiation, Vincristine Sulfate; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 157
States / cities: Tucson, Arizona • Duarte, California • Palo Alto, California + 114 more

Conditions: DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Peripheral Blood Stem Cell Transplantation, Placebo Administration; Procedure · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2027
U.S. locations: 140
States / cities: Scottsdale, Arizona • Duarte, California • Sacramento, California + 103 more

Conditions: CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Stage I Diffuse Large B-Cell Lymphoma, Stage II Diffuse Large B-Cell Lymphoma, Stage III Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma
Interventions: Carboplatin, Carfilzomib, Etoposide, Ifosfamide, Laboratory Biomarker Analysis, Pharmacological Study, Rituximab; Drug · Other · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Chronic Phase Chronic Myelogenous Leukemia
Interventions: Asciminib 40 MG, Asciminib 40 MG Twice Daily, Asciminib 80 MG daily, Imatinib, Nilotinib, Dasatinib; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 5
States / cities: Detroit, Michigan • Buffalo, New York • New York, New York + 2 more

Conditions: Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Tumor Treating Fields Therapy; Procedure · Drug · Radiation + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 332
States / cities: Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 252 more

Conditions: Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Surgical Procedure, Topotecan, Transabdominal Ultrasound, Vincristine, X-Ray Imaging; Procedure · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 178
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 138 more

Conditions: Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
Interventions: Biopsy Procedure, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Magnetic Resonance Elastography, Positron Emission Tomography, Radiation Therapy, Vincristine; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 166
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 129 more

Conditions: Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Kidney Neoplasm, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Desmoid Fibromatosis, Ganglioneuroma, Lymphoproliferative Disorder, Malignant Neoplasm, Malignant Solid Neoplasm, Melanocytic Neoplasm, Myeloproliferative Neoplasm, Neoplasm of Uncertain Malignant Potential, Neuroendocrine Neoplasm, Stromal Neoplasm
Interventions: Cytology Specimen Collection Procedure, Medical Chart Review; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 25 Years
Enrollment: 75,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2030
U.S. locations: 246
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 177 more

About this Roswell Park Comprehensive Cancer Center institution page

What this page lists: ClinicalTrials.gov records that list Roswell Park Comprehensive Cancer Center in Buffalo, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Roswell Park Comprehensive Cancer Center

Filter and sort this campus

Live official records

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer

Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use Cigarettes, E-cigarettes and Cannabis (Co-Tox Study)

Testing the SurVaxM Vaccine for Lung Cancer Prevention

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Project: Every Child for Younger Patients With Cancer

About this Roswell Park Comprehensive Cancer Center institution page